ClinicalTrials.gg
Status unknownNCT05628220SENSORIEL1Updated Nov 28, 2022

Motion Sickness Desensitization Using VR

An interventional study of physiotherapy in Motion Sickness, sponsored by University Hospital, Caen. Status unknown at 2 sites in France. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2022-11-28.

Sponsored by University Hospital, Caen · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 years 7 months after the study started (first participant enrolled Jan 2018, registered Sep 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 67 Years
Sex
All
01

Study summary

Evaluation of a virtual reality desensitization protocol on subjects with severe motion sickness and study of the role of the emotional component on the effectiveness of the therapy.

Read the detailed description

Motion sickness is a well-known syndrome, particularly at risk in children, with a maximum around the age of 12. All people are sensitive to motion sickness in childhood, probably related to the maturation of certain cognitive functions of a spatial nature, namely the perception of oneself and one's movements in one's environment. These symptoms regress with age for a part of the population but a large number of people will remain sensitive to certain conditions of displacement and generate symptoms that can be extremely disabling and handicapping in everyday life, particularly for professional activities. For example, some people can no longer use their car, some can no longer take the boat for professional activities in restrictive and/or extreme environments (sailors, scientists, workers, etc.). Behavioral, respiratory or medicinal therapies remain partially effective due to the lack of sufficient knowledge on the physiopathology of this syndrome classified in the field of sensory disorders. Very recently, techniques of sensory desensitization by visual stimulation have appeared, either optokinetic or in virtual reality mimicking the environment that causes this syndrome. This therapeutic approach seems to give empirically good results but only one study has shown it with optokinetic stimulation but it is to be evaluated for virtual reality.

The main objective of the study is therefore to evaluate the effectiveness of a sensory conflict protocol generated in virtual reality to reduce the severity of motion sickness. Each subject being his own control. An observational study was then designed to quantify the effectiveness of this technique carried out in a current way by the physiotherapists in the form of questionnaires supplemented by a posturographic evaluation of the sensory profile of the subjects. If the effectiveness is proven, this desensitization protocol could be optimized and more widely distributed. Furthermore, the analysis of the visuo-dependence variable (from the sensory profile) will indicate whether the use of a visual stimulus by virtual reality alone is sufficient or should be combined or compared with desensitization of other sensory modalities. The use of galvanic vestibular stimulation for the rehabilitation of vestibular pathologies or training programs based on the resolution of sensory conflicts could be envisaged in the future.

02

Conditions studied

  • Motion Sickness

Keywords

  • vestibular system
  • posture
  • anxiety
  • nausea
  • motion sickness
  • visually induced motion sickness
03

In context

Motion Sickness

50 studies on the registry are indexed under Motion Sickness; 9 are open to participants now.

This study's planned enrollment of 30 is below the median of 59 across 44 interventional studies indexed under Motion Sickness.

Browse Motion Sickness studies →

Lead sponsor

University Hospital, Caen is the lead sponsor of 512 studies on the registry; 82 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 67 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Suffering from motion sickness inducing a functional disability requiring a change in the mode of travel, or suffering from motion sickness disabling to exercise a leisure or professional activity involving a mode of locomotion.

Exclusion criteria

Exclusion Criteria:

  • Pregnant woman
  • History of severe ENT or ophthalmologic pathologies.
  • Chronic treatment with an anticholinergic or anti-histamine medication.
  • Participating in another biomedical research protocol during the same period
  • Person under guardianship or curatorship
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Cohort of motion sickness

    one group of patient

    Other: physiotherapy

Interventions

  • Otherphysiotherapy

    rehabilitation through using session of virtual reality desensitization

06

What researchers measure

Primary outcomes

  1. motion sickness severity

    simulator sickness questionnaire (0-64)

    Time frame: day 0 (day before the first session of rehabilitation)

  2. motion sickness severity

    simulator sickness questionnaire (0-64)

    Time frame: day 30 (day after the end of rehabilitation)

Secondary outcomes

  1. Emotion

    The State-Trait Anxiety Questionnaire (0-80)

    Time frame: day 0 (day before the first session of rehabilitation)

  2. Emotion

    The State-Trait Anxiety Questionnaire (0-80)

    Time frame: day 30 (day after the end of rehabilitation)

  3. Posture

    postural measurement (gravity center ellipse)

    Time frame: day 0 (day before the first session of rehabilitation)

  4. Posture

    postural measurement (gravity center ellipse)

    Time frame: day 30 (day after the end of rehabilitation)

07

Study locations

2 of 2 sites recruiting
  • Caen University Hospital
    Caen, 14033, France
    Recruiting
    • Stéphane BESNARD, MD, PhD · Contactstephane.besnard@unicaen.fr · +33231065332
    • Stéphane BESNARD, MD, PhD · Principal investigator
    • Martin HITIER, MD, PhD · Sub investigator
    • Sylvain MOREAU, MD, PhD · Sub investigator
    • Laetitia PLISSON, MD · Sub investigator
  • Frédéric Xavier
    Vitrolles, 13127, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05628220
Responsible party
Sponsor
First posted
Nov 28, 2022
Start date
Jan 10, 2018
Primary completion
Feb 28, 2023 (estimated)
Completion
Feb 28, 2023 (estimated)
Last update
Nov 28, 2022

Study contacts

stephane besnard, MD, PhD
Contact
stephane.besnard@unicaen.fr
+33677978649
stephane BESNARD, Md,PhD
principal investigator · University Hospital, Caen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion